anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To provide the title ointment having improved stability of an ointment containing esterified corticosteroid (an anti-inflammatory agent), and having excellent stability and transcutaneous absorbability, by compounding an organic acid and a glycol to the ointment. CONSTITUTION:An ointment containing 0.01-1% esterified corticosteroid such as difluprednate, betametasone valerate, hydrocortisone butyrate propionate, etc., is compounded with (A) an organic acid, preferably a polybasic acid such as succinic acid, phthalic acid, tartaric acid, citric acid, malonic acid, etc. and (B) a glycol, e.g. polyethylene glycol (molecular weight: 200-600), propylene glycol, 1,3-butylene glycol, etc. The amount of the component A is 0.005-20%, especially 0.05-5% based on the component B, and that of the component B is 2-15% based on the whole ointment. The long-term storage stability of the ointment can be improved by this process.
PURPOSE:To prepare synthetic lamellar magnesium phyllosilicate having emulsifiability, large specific surface area, and excellent adsorption characteristics, by carrying out hydrothermal treatment of a magnesium-containing raw material and a silica-containing component composed of an active silicic acid compound. CONSTITUTION:Active silica obtained by the acid-treatment of a clay mineral, or active aluminosilicate is used as the raw material of the objective compound. The raw material contains about >=20wt% particles having particle diameter of <=5mu. An aqueous slurry of a mixture of (A) the above silica-containing raw material and (B) a magnesium-containing raw material (e.g. magnesium oxide, magnesium hydroxide, etc.) at a SiO2:MgO molar ratio of about 3:4 (solid concentration: about 2-30wt%), is charged in an autoclave, and heated at about 100-200 deg.C to effect the hydrothermal reaction of the components under the autogeneous steam pressure. The synthetic lamellar megnesium phyllosilicate obtained by the reaction has the following charcteristics: Main component has the composition of formula (n<=5) and a mismatching index ( I S) of >=3, BET specific surface area of >=300m<2>/g, and methylene blue discoloration activity of >=100ml/g.
The present invention relates to an artificial intelligence deep learning-based discrimination apparatus for a skin disease. More specifically, after the artificial intelligence deep learning-based discrimination apparatus for a skin disease classifies skin disease data set image information into a class which is set in advance by using one among a two-dimensional convolution neural network (CNN), a three-dimensional CNN, and a virtual three-dimensional CNN, the artificial intelligence deep learning-based discrimination apparatus for a skin disease stores and manages the skin disease data set image information by learning the skin disease data set image information. The artificial intelligence deep learning-based discrimination apparatus for a skin disease determines where a skin disease image obtained from a user passing user authentication belongs among skin cancer, a skin color disease, an infectious disease, and normal skin. Moreover, the artificial intelligence deep learning-based discrimination apparatus for a skin disease provides the determination for a user terminal. At the same time, the artificial intelligence deep learning-based discrimination apparatus for a skin disease provides the determination for an image-based skin disease AI deep learning automatic learning unit to perform relearning. The artificial intelligence deep learning-based discrimination apparatus for a skin disease comprises the image-based skin disease AI deep learning automatic learning unit (100) and a target image class discrimination unit (200).
Neutrophils are sentinel immune cells with essential roles for antimicrobial defense. Most of our knowledge on neutrophil tissue navigation derived from wounding and infection models, whereas allergic conditions remained largely neglected. Here, we analyzed allergen-challenged mouse tissues and discovered that degranulating mast cells (MCs) trap living neutrophils inside them. MCs release the attractant leukotriene B4 to re-route neutrophils toward them, thus exploiting a chemotactic system that neutrophils normally use for intercellular communication. After MC intracellular trap (MIT) formation, neutrophils die, but their undigested material remains inside MC vacuoles over days. MCs benefit from MIT formation, increasing their functional and metabolic fitness. Additionally, they are more pro-inflammatory and can exocytose active neutrophilic compounds with a time delay (nexocytosis), eliciting a type 1 interferon response in surrounding macrophages. Together, our study highlights neutrophil trapping and nexocytosis as MC-mediated processes, which may relay neutrophilic features over the course of chronic allergic inflammation.
Three hundred thirty-six gelatin coated 450 mg capsules containing approximately 180 mg of EPA and 135 mg of DHA will be dispensed. Patients are to take 12 capsules daily with meals, either once daily (12 capsules with one meal) or divided twice daily (e.g., six with breakfast and six with dinner).
Envarsus XR (Tacrolimus Extended Release Oral Tablet) will be administered once daily at initial weight-based dose of 0.12 mg/kg. Dosing and monitoring thereafter predicated on clinical judgment to a minimum whole blood tacrolimus concentration of at least 8 ng/mL. When possible, patients will receive their daily dose of Envarsus using the fewest number of pills possible.
FIELD: medicine, virology. SUBSTANCE: method involves parenteral administration of preparations containing interferon inductor and/or immunomodulating agent before or at period of pathogen incorporation in organism by aerogenic way. These preparations were administrated by intranasal route simultaneously with parenteral administration at the same doses. Prophylaxis preparations: reaferon or ridostin, or reaferon with ridostin, or reaferon with polyribonate, or reaferon with ridostin and polyribonate that were administrated in organism twice per a day at the following total doses: reaferon (1.0-100.0) x 10IU/kg; ridostin 1.0-8.0 mg/kg, and polyribonate 10.0-100.0 mg/kg. Method is used for nonspecific immunoprophylaxis of viral infection. EFFECT: enhanced prophylaxis action. 4 tbl
RATIONALE: This study presents the first comprehensive analysis and mapping of scientific research on point-of-care testing (POCT) in infectious diseases, filling a gap in understanding the evolving landscape of this field. The identification of research themes and global contributions offers valuable insights.
AIMS AND OBJECTIVES: This manuscript aims to analyse and map scientific research on POCT in the context of infectious diseases.
METHODS: The study employed a comprehensive search strategy using terms related to POCT and infectious diseases. The search was conducted on the Scopus database, refining results based on inclusion and exclusion criteria. The dataset of 1719 research articles was then subjected to descriptive analysis and mapping using VOSviewer.
RESULTS: The research findings indicate an exponential growth in POCT-related publications, with 46.8% published post the COVID-19 pandemic. Plos One journal led in publication frequency, and Biosensors and Bioelectronics received the highest citations per article. North America and Western Europe dominated contributions, with notable participation from China, South Africa, and India. The research landscape revealed the following research themes: detection technologies, human immunodeficiency virus (HIV)/sexually transmitted infection (STI) diagnosis, antibiotic optimisation, and schistosomiasis. Clinical trials focused on antibiotic prescribing, HIV, STIs, and specific infections. The findings suggest a shifting landscape towards POCT, emphasising the need for future planning and investment in healthcare systems. The research identifies areas for future exploration, such as the impact of POCT on antibiotic prescribing and its role in combating infectious diseases in low- and middle-income countries.
CONCLUSION: Implementation of POCT has the potential to revolutionise infectious disease management, improve patient outcomes, and reduce the global burden of diseases. Better public awareness, healthcare team management, and planning for POCT at entry points are crucial for societal benefit. Results demonstrated the evolving role of POCT in infectious disease management and prevention.
Traumatic anterior communicating artery (AcomA)-cavernous sinus (CS) fistula is rare. Flow diverter (FD) deployment associated with coiling may be an alternative but has never been reported. We reported such a case. A 61-year-old man who was involved in a traffic accident presented with progressive exophthalmos for 2 weeks. Digital subtraction angiography showed a fistula between the AcomA and CS. First, the fistula was coiled. Then, the FD was deployed to cover the rupture point of the AcomA. The fistula was obliterated. Postoperatively, the patient recovered well, and his eye symptoms disappeared. Follow-up angiography showed no recurrence of the fistula. Therefore, for traumatic AcomA-CS fistula, FD deployment associated with coiling may be a feasible alternative.
Compositions having one or more oil-in-water dispersions of (i) particles of one or more hydrophobic agent(s), (ii) one or more polymer or copolymer fragments, or combinations thereof, and (iii) an aqueous-solute fluid. The particles of one or more hydrophobic agent(s) are present in an amount from about 0.01% wt. to about 70% wt.. the one or more polymer or copolymer fragments, or combinations thereof are present in an amount from about 0.01% wt. to about 10% wt., and the aqueous-solute fluid is present in an amount from about 1.0% wt. to about 98.5% wt., all based on the total weight of the composition. The one or more polymer or copolymer fragments, or combinations thereof, are sufficient to stabilize the particles of one or more hydrophobic agent(s) in the dispersion, at a level from about 0.05% w/w to about 70% w/w of the one or more hydrophobic agent(s), in the dispersion. Processes of making the dispersions, and method of use of the dispersions. The dispersions are useful, for example, in nutritional, pharmaceutical, biomedical, cosmetic, food, animal care, veterinary care, household, pet care, and other applications.
INTRODUCTION: Metabolic-dysfunction Associated Steatotic Liver Disease (MASLD) is a common cause of chronic liver disease. This review assessed the efficacy of a Low-Calorie Diet (LCD) on liver health and body weight in people living with MASLD and obesity.
METHODS: The study was registered with PROSPERO (CRD42021296501), and a literature search was conducted using multiple databases. The key inclusion criteria were randomised controlled trials or cohort studies, obesity/overweight and MASLD. Two authors screened abstracts, reviewed full texts and performed data extraction and quality assessment. The primary outcome was the change in the serum ALT, and secondary outcomes included the changes in the serum AST, intrahepatic lipid content (IHL), quantified non-invasively via MRI/MRS, and body weight.
RESULTS: Fifteen studies were included. The LCD reduced body weight by 9.1 kg versus the control (95%CI: -12.4, -5.8) but not serum ALT (-5.9 IU/L, -13.9, 2.0). Total Dietary Replacement (TDR) reduced IHL by -9.1% vs. the control (-15.6%, -2.6%). The Mediterranean-LCD for ≥12 months reduced ALT (-4.1 IU/L, -7.6, -0.5) and for 24 months reduced liver stiffness versus other LCDs. The Green-Mediterranean-LCD reduced IHL, independent of body weight. Limited studies assessed those of Black or Asian ethnicity, and there was heterogeneity in the methods assessing the liver fat content and fibrosis.
CONCLUSIONS: In people with MASLD and obesity, an LCD intervention reduces IHL and body weight. Trials should focus on the recruitment of Black and Asian ethnicity participants.
Coenzyme Q10 (CoQ10) occurs naturally in the body and possesses antioxidant and cardioprotective effects. Cardiotoxicity has emerged as a serious effect of the exposure to cadmium (Cd). This study investigated the curative potential of CoQ10 on Cd cardiotoxicity in mice, emphasizing the involvement of oxidative stress (OS) and NF-κB/NLRP3 inflammasome axis. Mice received a single intraperitoneal dose of CdCl2 (6.5 mg/kg) and a week after, CoQ10 (100 mg/kg) was supplemented daily for 14 days. Mice that received Cd exhibited cardiac injury manifested by the elevated circulating cardiac troponin T (cTnT), CK-MB, LDH and AST. The histopathological and ultrastructural investigations supported the biochemical findings of cardiotoxicity in Cd-exposed mice. Cd administration increased cardiac MDA, NO and 8-oxodG while suppressed GSH and antioxidant enzymes. CoQ10 decreased serum CK-MB, LDH, AST and cTnT, ameliorated histopathological and ultrastructural changes in the heart of mice, decreased cardiac MDA, NO, and 8-OHdG and improved antioxidants. CoQ10 downregulated NF-κB p65, NLRP3 inflammasome, IL-1β, MCP-1, JNK1, and TGF-β in the heart of Cd-administered mice. Moreover, in silico molecular docking revealed the binding potential between CoQ10 and NF-κB, ASC1 PYD domain, NLRP3 PYD domain, MCP-1, and JNK. In conclusion, CoQ10 ameliorated Cd cardiotoxicity by preventing OS and inflammation and modulating NF-κB/NLRP3 inflammasome axis in mice. Therefore, CoQ10 exhibits potent therapeutic benefits in safeguarding cardiac tissue from the harmful consequences of exposure to Cd.
A system and method to receive a request for a patient-specific surgical plan, create the requested plan, and provide it to a surgeon is disclosed. A Planning server may receive information regarding a patient, such as one or more files or objects, and an order from a surgeon for a surgical plan. A Plan Development client may include a surgical planning module that accesses the one or more files or objects, and creates a computer-generated, three-dimensional model of the patient anatomy. The planning module of the Plan Development client also may create an electronic surgical plan, and may transmit the plan to the Planning server. The ordering surgeon may be notified of the availability of the plan, and may access the plan stored at the Planning server through a surgeon client. The ordering surgeon may utilize the remotely generated surgical plan during the surgical procedure on the patient.
The invention relates to a preparation method for Pouzolzia zeylanica (L.) Benn. var. microphylla (Wedd.) W. T. Wang flavonoids. The method comprises the following steps: using Pouzolzia zeylanica (L.) Benn. var. microphylla (Wedd.) W. T. Wang as a raw material, carrying out hot extraction with petroleum ether having a boiling range of 60 to 90 DEG C, carrying out extraction with an ethanol solution having a concentration of 50 to 70% twice to three times, condensing the extracts to form an extractum, adding acid water to disperse the extractum, carrying out filtering to obtain insoluble substances, and separating the insoluble substances with a macroporous resin to obtain Pouzolzia zeylanica (L.) Benn. var. microphylla (Wedd.) W. T. Wang flavonoids. The content of flavone in the obtained flavonoids is as much as 65 to 85%. The method provided in the invention has a simple process and produces a product with high purity.
The present invention relates generally to the use of vitamin B12 (cobalamin or cyanocobalamin) alone or in combination with other photoprotective agents, including specifically other vitamins such as vitamin B9 (folic acid or folate) and vitamin B3 (niacin or niacinamide), or any chemical derivative of these vitamins and their salts, as a filter to protect cells against the damaging effects of ultraviolet (UV) light. The invention is, in one aspect, a method of reducing the rate of UV damage to cells exposed to a UV light source, by treating the cells with the vitamin composition, either alone or in combination with other photoprotective agents. Other aspects of the invention are compositions comprising effective amounts of vitamin B12 alone or in combination with other photoprotective agents including vitamin B9 and vitamin B3 and a pharmaceutically-acceptable carrier, that are useful in protecting cells, particularly skin cells, against the burning, genotoxic (mutagenic and carcinogenic), immunosuppressive and photoaging effects of UV light, especially sunlight. The invention has application as a UV light filter in oral preparations including tablets and drinks, topical creams, lotions, sprays, wipes and cosmetics. The invention also has application as a medicinal treatment for dermatological conditions caused by exposure to sunlight, such as actinic keratoses, photodermatitis, photo-induced (discoid) lupus erythematosus and the photosensitizing effects of a variety of drugs used commonly in clinical practice (e.g. certain antihistamines, ACE inhibitors, and antibiotics such as tetracycline).
Patients are eligible to receive up to 2 inductions and up to 2 consolidations with liposomal cytarabine-daunorubicin for injection. The number of inductions and consolidations a patient received will depend on response.
BACKGROUND: Acute abdominal pain in paediatric patients is a common presentation to the Emergency Department (ED). The COVID-19 pandemic had a significant impact on the health care sector leading to a decline in hospital attendance.
AIMS: We compare the burden of paediatric abdominal pain 1 year before and after the start of the COVID-19 pandemic in an Irish ED.
METHODS: A retrospective cohort study was conducted in a tertiary hospital. Ethical approval was obtained. Data was collected from January 1 to June 30, 2019, and 2021. Patients' charts were accessed using Therefore® software. Key variables were extracted and summarised in Microsoft Excel tables. Univariate and multivariate data analysis were conducted in SPSS® software.
RESULTS: Six hundred sixty-one (2019) and 479 (2021) patient records were evaluated. There was a 28% reduction in case presentations during pandemic months. Age group, sex and attending discipline were similar for both years. Rates of imaging were significantly higher in 2021 (22.5% vs. 10.6%). Overall admission rate was higher in 2021 (37% vs. 25%, p < 0.001). Viral gastroenteritis decreased (13%) and non-specific diagnosis increased (46%) in 2021. Fewer children re-presented in 2021 (13%).
CONCLUSIONS: The COVID-19 pandemic had an impact on the presentation, investigations and admission rates of abdominal pain in the ED. Our study highlights the need for increased awareness of severe abdominal pain signs and symptoms in paediatric patients and importance for diagnostic accuracy. Improving patient flow through the ED and having clear guidelines for staff and parents can optimise clinical practice and improve patient outcomes.
Degenerative spine disease is a normal part of the aging process. This degeneration can sometimes cause significant pain and limit normal movement.

The pain can be from many sources. For patients being enrolled into this study the pain has been diagnosed to be primarily as a result of a condition called spinal stenosis. The current standard of care for the treatment of moderate to severe spinal stenosis is a surgical procedure that relieves the pressure on the spinal cord and nerves is called decompression surgery. The surgeon removes the tissue and bone that are causing the narrowing thus relieving the pinching of the spinal cord and nerve roots. After surgery, the patient may have a spine that is too unstable. In other words the muscles and ligaments around the spine have to work too hard to maintain normal posture and to control movement. For many years those patients with unstable backs have received fusion therapy. Fusion is the development of bone between the vertebra to stabilize the spine and prevent motion. This is done by inserting a bone graft around the vertebra being treated and placing a rigid brace called a fusion device to prevent movement. Eventually bone will form between the vertebra and the spine will become "fused".

In this study we will be conducting research to evaluate a new, investigative medical device that is designed to brace and support the spine just like fusion but without fusing in the patient's spine. Devices that do this are called "motion preserving" or "dynamic stabilizing" spinal devices. The investigational device that is being evaluated in this study is called the Stabilimax NZ® Dynamic Spinal Stabilization System. The Stabilimax NZ® is inserted and fixed to the vertebra by means of pedicle screws in exactly the same way a fusion device is inserted and attached. The only difference is that for the Stabilimax NZ® no bone graft will be placed around or between the vertebra to promote bone growth for fusion. Patients in the study will receive either the Stabilimax NZ® or will receive a fusion procedure. The study is a randomized controlled clinical trial using a 2:1 investigational:control randomization scheme. The study will enroll 480 patients at approximately 20 investigational sites across the United States.
The invention discloses a compound radix peucedani heat-clearing and cough-reliving capsule, belonging to the technical field of medicines. The compound radix peucedani heat-clearing and cough-reliving capsule is prepared from radix peucedani serving as a main raw material in coordination with perilla fruits, dried orange peel, fried apricot kernels and crude liquoric root serving as auxiliary materials. Multiple types of medicinal materials are compounded together, so that the pharmaceutical effect is promoted, and the defect of a single medicinal material is overcome. The compound radix peucedani heat-clearing and cough-reliving capsule product has good mouthfeel and remarkable heat-clearing and cough-reliving effects and is long in shelf life. A production process for the compound radix peucedani heat-clearing and cough-reliving capsule disclosed by the invention is scientific, effective, simple and convenient, and is easy to operate. Purification is performed specific to the characteristics of different medicinal raw materials, so that active ingredients are retained to the maximum extent, and the requirements of different consumers on health can be met.
1455889 Veterinary compositions ABIC Ltd 19 July 1974 [20 July 1973] 32064/74 Heading A5B Compositions for the treatment of Cocciodiosis comprise a Robenidine salt, a water-soluble organic solvent and a water-soluble surface active agent, the solvent and the surface-active agent being miscible with each other. The Robenidine salt may be the hydrochloride, the hydrobromide or the nitrate. The solvent may be glycol, glycerol, propylene glycol, a polyethylene glycol, a polypropylene glycol, tetraglycol, glycerol formal, dimethyl sulphoxide, or dimethylformamide. The surface active agent may be non-ionic, cationic or anionic. The compositions may be administered in the drinking water of the animal, e.g. a fowl.